跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML2881

Sigma-Aldrich

R-VK4-40

≥98% (HPLC)

别名:

R-VK4-40, N-[(3R)-4-[4-(2-Chloro-3-ethylphenyl)-1-piperazinyl]-3-hydroxybutyl]-1H-indole-2-carboxamide

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C25H31ClN4O2
CAS号:
2133454-52-9
分子量:
454.99
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

O=C(C1=CC2=C(C=CC=C2)N1)NCC[C@H](CN3CCN(C4=CC=CC(CC)=C4Cl)CC3)O

InChI

1S/C25H31ClN4O2/c1-2-18-7-5-9-23(24(18)26)30-14-12-29(13-15-30)17-20(31)10-11-27-25(32)22-16-19-6-3-4-8-21(19)28-22/h3-9,16,20,28,31H,2,10-15,17H2,1H3,(H,27,32)/t20-/m1/s1

InChI key

OIRZLTZLOKARTG-HXUWFJFHSA-N

生化/生理作用

R-VK4-40 is an orally available, highly selective and potent dopamine D3 receptor (D3R) antagonists that does not exhibit unwanted cardiovascular effects. R-VK4-40 attenuates oxycodone induced rewards without compromising antinociceptive effects in rats. It reduces oxycodone self-administration and suppress naloxone-caused opioid withdrawal.
orally available, highly selective and potent dopamine D3 receptor (D3R) antagonists that does not exhibit unwanted cardiovascular effects

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chloe J Jordan et al.
Neuropharmacology, 158, 107597-107597 (2019-04-12)
Prescription opioid abuse is a global crisis. New treatment strategies for pain and opioid use disorders are urgently required. We evaluated the effects of R-VK4-40, a highly selective dopamine (DA) D3 receptor (D3R) antagonist, on the rewarding and analgesic effects
Chloe J Jordan et al.
The Journal of pharmacology and experimental therapeutics, 371(3), 602-614 (2019-09-29)
Opioid and cocaine abuse are major public health burdens. Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder. Dopamine D3 receptor
Anver Basha Shaik et al.
Journal of medicinal chemistry, 62(20), 9061-9077 (2019-09-19)
Dopamine D3 receptors (D3R) play a critical role in neuropsychiatric conditions including substance use disorders (SUD). Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogues as high affinity and selective D3R lead molecules for the treatment of opioid use disorders (OUD).

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门